Filing Details
- Accession Number:
- 0001209191-18-019209
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-13 16:22:34
- Reporting Period:
- 2018-03-12
- Accepted Time:
- 2018-03-13 16:22:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 816284 | Celgene Corp | CELG | Pharmaceutical Preparations (2834) | 222711928 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1276550 | J James Loughlin | C/O Celgene Corporation 86 Morris Avenue Summit NJ 07901 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-03-12 | 9,250 | $27.18 | 33,611 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-03-12 | 9,250 | $92.01 | 24,361 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2018-03-12 | 9,250 | $0.00 | 9,250 | $27.18 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2018-03-17 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,800 | Indirect | Family Trust |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $91.46 to $92.47, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- The option was fully exercisable.
- The option was issued pursuant to the Company's 1995 Non-Employee Directors' Incentive Plan.
Billionaire Hedge Funds
